Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349946 · ClinicalTrials.gov registry record
Diffusion Weighted Imaging Evaluation for Understanding Stroke Evolution Study-2 (DEFUSE-2)
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 138
- Enrollment target
NCT01349946: Completed study, sponsored by Stanford University.
NCT01349946 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 138 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01349946 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 138 participants
- Enrollment target
Study Summary
Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study 2 (DEFUSE 2) is a multi-center pilot study to determine if cerebral perfusion imaging can help identify which patients, who are ineligible for intravenous tissue plasminogen activator (iv tPA) therapy or have failed iv tPA therapy, are most likely to benefit from an endovascular clot removal procedure.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-12 |
What the finished NCT01349946 record still lists
NCT01349946 is an observational study that tracks outcomes without assigning an intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01349946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01349946 about?
NCT01349946 is a clinical study titled "Diffusion Weighted Imaging Evaluation for Understanding Stroke Evolution Study-2 (DEFUSE-2)". Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution Study 2 (DEFUSE 2) is a multi-center pilot study to determine if cerebral perfusion imaging can help identify which patients, who are ineligible for intravenous tissue plasminogen activator (iv tPA) therapy or have failed ...
What is the current status of trial NCT01349946?
This trial is currently completed. The enrollment target is 138 participants. The study started on 2008-06. Estimated completion is 2011-12.
Who is sponsoring clinical trial NCT01349946?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia